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Abstract
Purpose: Even today, total knee arthroplasty (TKA) is associated with venous thromboembolism (VTE). The purpose
of our study is to report the incidence of postoperative VTE and to compare the efficacy of commonly used orally
administered antithrombotic agents.
Materials and methods: Seven hundred ad ninety-nine patients who underwent primary TKA were retrospectively
reviewed. The patients were prescribed one of three antithrombotic agents: aspirin (n = 168), rivaroxaban (n = 117),
or apixaban (n = 514). Before surgery, patient demographics and risk factors were matched via propensity scoring.
After surgery, all three groups took the agent for 7 days and underwent ultrasonography to check for VTE.
Results: The overall incidence of postoperative VTE was 15.4% (123/799). Only one patient developed symptomatic
VTE. Female sex and staged bilateral TKA were risk factors for postoperative VTE. The postoperative VTE rates in the
aspirin, rivaroxaban, and apixaban groups were 16.2%, 6.0%, and 17.1%, respectively, significantly lower in the
rivaroxaban group (p < 0.02). The majority of VTEs in all three groups were calf-vein thromboses.
Conclusions: All agents showed enough efficacy as antithrombotic agents. Considering that aspirin is inexpensive,
aspirin is a cost-effective option for preventing postoperative VTE.
Keywords: Venous thromboembolism, Total knee arthroplasty, Antithrombotic agent, Aspirin, Rivaroxaban,
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Introduction
Total knee arthroplasty (TKA) is effective for treating
advanced degenerative arthritis of the knee. Patients
undergoing artificial joint surgery have an average of
two to three comorbidities and 33% have five or more
[1, 2], increasing the risk for complications after surgery
[3]. Given the increased numbers of artificial joint sur-
geries in elderly patients, the numbers of patients with
comorbidities will likely increase [4], as will the rate of
complications. Of these, venous thromboembolism
(VTE) is a principal cause of mortality in the 3 to 6
months after surgery, and may progress to a pulmonary
embolism [5]. The incidence of VTE after TKA varies
from 1.5% to 41.7% [6]. Common risk factors for VTE
include a previous history of VTE, venous insufficiency,
congenital heart failure, obesity, trauma, immobilization,
and infectious disease [3, 7]. Prevention of postoperative
VTE requires significant resources [7].
Mechanical devices and pharmacological agents are
used to this end. Antithrombotic agents include enoxa-
parin, aspirin, rivaroxaban, and apixaban [8–10]. Enoxa-
parin is a low-molecular-weight heparin (LMWH). The
American College of Clinical Pharmacy (ACCP) guide-
lines recommended LMWH as an antithrombotic agent
in orthopedic surgery [11]. However, it is uncomfortable
for patients because enoxaparin is taken by subcutane-
ous injection. Aspirin is an antiplatelet agent that irre-
versibly inhibits the cyclooxygenase enzyme. Aspirin is
an inexpensive oral agent and is recommend as an anti-
thrombotic agent to prevent VTE in various guidelines
[11, 12]. Its use is associated with a postoperative VTE
frequency of 2.3–17.8% [8]. Apixaban is a direct-acting
orally administered anticoagulant (DOAC), a reversible
direct inhibitor of both free and clot-bound factor Xa.
The ACCP guidelines recommend apixaban as an anti-
thrombotic agent in arthroplasty surgery [11]. Its use is
associated with a postoperative VTE frequency of 0.7–
9% [10, 13]. Rivaroxaban is another factor Xa inhibitor
(a DOAC) associated with a postoperative VTE fre-
quency of 0.7–3.7% [14, 15]. Like apixaban, it is recom-
mended as an antithrombotic agent in arthroplasty
surgery [11].
DOACs are widely used antithrombotic agents; many
reports on drug efficacies and safety have appeared.
Compared to enoxaparin (a low-molecular-weight hep-
arin (LMWH) widely used in the past), DOACs are simi-
larly safe (associated with low bleeding risks) but more
effective [16]. Apixaban is the DOAC with the lowest
bleeding risk, but with no loss of efficacy [17]. Aspirin is
safest in patients with postoperative anemia or who re-
quire transfusions, being better than LMWH but less ef-
fective than DOACs [18].
Previous studies on antithrombotic agents preventing
VTE after TKA have compared LMWH and DOACs, or
various DOACs. However, the most commonly used or-
ally administered antithrombotic agents (aspirin, rivarox-
aban, and apixaban) have not been compared. Large-
scale studies are required to explore the incidence of
VTE in patients taking antithrombotic agents, and the
efficacies of the various drugs.
The goals of this study were: (1) to report the inci-
dence of postoperative VTE and the associated risk fac-
tors, and (2) to compare the efficacy of three commonly
used orally administered antithrombotic agents.
Materials and methods
Study subjects
The study was performed as a retrospective review using
propensity score-matching. From January 2014 to May
2019, patients scheduled for primary TKA to treat de-
generative knee arthritis were enrolled after providing
informed consent and were prescribed one of three or-
ally administered antithrombotic agents depending on
the period. (From January 2014 to July 2014: rivaroxaban
(Xarelto; Bayer, Germany), From July 2014 to July 2017:
apixaban (Eliquis; BMS/Pfizer, New York, NY, USA),
From November 2017 to December 2018: aspirin
(Astrix; Boryung, Korea). Initially, 857 patients were en-
rolled. The exclusion criteria were simultaneous bilateral
TKA (n = 6) and preoperative VTE (n = 52).
Ultimately, 799 patients (83 male and 716 female) were
enrolled. Of them, 438 patients underwent unilateral
TKA, and 361 patients underwent staged bilateral TKA.
Bilateral staged TKA was performed at 1-week intervals;
bilateral TKA surgery performed at intervals > 4 weeks
was defined as two unilateral TKAs. In all, 168 patients
were prescribed aspirin, 117 were given rivaroxaban, and
514 took apixaban (Fig. 1).
To address potential bias and confounding factors,
rigorous adjustment was conducted using 1:1 propensity
score-matching (caliper 0.2); the matching criteria were
age, sex, body mass index (BMI), type of surgery, and
medical history. After matching, 117 patients were
remained in each agent (Table 1).
Routine protocol
Patients were admitted 2 days prior to surgery to check
for preoperative VTE via computed tomographic (CT)
venography or ultrasonography. Antithrombotic agents
commenced on postoperative day 1. Patients undergoing
staged bilateral TKA took aspirin between the two oper-
ations, and they commenced a designated antithrom-
botic agent on day 1 after the second operation. The
antithrombotic continued until postoperative day 7. All
patients were screened for VTE by ultrasonography on
postoperative day 6 after unilateral TKA or the second
operation of staged bilateral TKA. Because ultrasonog-
raphy has high sensitivity and specificity, additional tests
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were performed only in the presence of symptomatic VTE
[19]. All patients were followed up at outpatient clinic at
1month, 3months, 6 months, and 1 year after surgery.
The drug doses were aspirin 300mg daily, rivaroxaban 10
mg daily, and apixaban 2.5mg twice daily [13, 20–22].
Other than antithrombotic agents, drugs that could
affect thrombotic tendency were not used. In some pa-
tients, intra-articularly administered tranexamic acid (IA-
TXA) was used, but it it known that IA-TXA does not in-
crease the risk of thromboembolic adverse events [23].
Additionally, all patients wear compression stocking and
used intermittent pneumatic compression devices.
VTE detection
The lower-extremity thrombosis (LET) classification sys-
tem was used (class I: calf vein thrombosis, class II: pop-
liteal and femoral vein thrombosis, class III: common
femoral/iliac vein thrombosis, and class IV: inferior vena
caval thrombosis) [24]. If pain, swelling, redness, or
warmth was evident, VTE was considered symptomatic.
Surgical technique
A single surgeon performed all surgeries via an anterior
midline skin incision and a standard mid-vastus arthrot-
omy with tourniquet inflation. The posterior cruciate
ligament was resected, tibial extramedullary guide was
used and a posterior-stabilized knee prosthesis with a fixed
bearing was implanted in all cases. Patellar resurfacing was
routine and cement fixation was used in every case. After
tourniquet deflation and meticulous bleeding control, a suc-
tion drain was inserted and the capsule, vastus muscle fascia,
and medial patellar retinaculum were closed. After wound
closure with a sterile dressing, tight Jones compression was
performed in the extension position.
Statistical analyses
The results are given as means with standard deviations (SDs).
Categorical variables were analyzed using Pearson’s chi-square
test and continuous variables (age and BMI) were compared
employing Student’s t test. Continuous variables subjected to
multiple comparisons between agent groups were analyzed
using analysis of variance (ANOVA). Propensity scores were
estimated via multiple logistic regression analyses including all
relevant covariates (age, sex, BMI, type of surgery, and medical
history). The antithrombotic groups exhibited 1:1 ratio with
calipers equal to 0.2 of the SD of the logistic of the propensity
score. Standardized mean differences were estimated to bal-
ance all reference covariates before and after matching. All
statistical analyses were performed using SPSS ver. 23.0 for
Windows (SPSS Inc., Chicago, IL, USA) and RStudio ver.
1.2.5033 for Windows (RStudio Inc., Boston, MA, USA).
Fig. 1 Flowchart of reasons for exclusion and propensity score-matching
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Results
The incidence of postoperative VTE was 15.4% (123/799),
the majority of which were calf vein thromboses (98.4%,
121/123). Only one patient developed symptomatic VTE
and was prescribed apixaban (an antithrombotic agent).
This patient visited the internal medicine clinic and was
prescribed apixaban for the next 5months. And then,
treatment concluded without any problem.
To determine risk factors for postoperative VTE, the
799 patients were divided into 676 without VTE and 123
with VTE. It was found that female sex and staged bilat-
eral TKA were significant VTE risk factors with odds ra-
tios of 3.94 and 1.75, respectively (Table 2).
After propensity score-matching, no significant differ-
ences in the demographic characteristics of the three anti-
thrombotic groups were evident, except for age (Table 1).
The incidences of postoperative VTE in the aspirin, rivar-
oxaban, and apixaban groups were 16.2%, 6.0%, and 17.1%
(Table 3), significantly lower in the rivaroxaban group
(p = 0.02). The majority of VTEs in all three groups were
calf vein thromboses. One popliteal VTE developed in the
aspirin group, but did not progress to a pulmonary
embolism.
Discussion
The incidence of postoperative VTE was 15.4%, princi-
pally calf vein thrombosis. Covariate analyses of postop-
erative VTE frequencies showed that female sex and
bilateral staged TKA were VTE risk factors. Of the three
antithrombotic agents, rivaroxaban had the lowest inci-
dence of postoperative VTE and majority of VTEs in all
three groups were calf vein thromboses.
The incidence of postoperative VTE is 38.8–48.6% if
antithrombotic agents are not given after TKA [7, 25].
All subjects in this study were prescribed antithrombotic
agents; the postoperative VTE rate was 15.4%. Of the
123 VTE patients, only two were popliteal vein throm-
boses and the rest were calf vein thromboses.
Various demographics were investigated to determine
postoperative VTE risk factors. Statistical analyses fo-
cused on age, BMI, type of surgery, medical history, and
previous anticoagulant usage. Sex and unilateral or
staged bilateral TKA were associated with postoperative
VTE. Female patients were 3.69-fold (1.33- to 10.3-fold)
more likely than male patients to develop VTE, and
those undergoing staged bilateral TKA were 1.68-fold
(1.14- to 2.48-fold) more likely to develop VTE than
Table 1 Summary of the demographic characteristics of the study groups

















Age (years) 68.7 ± 5.6 75.9 ± 6.0 71.1 ± 6.9 0.001 71.1 ± 4.5 75.9 ± 6.0 76.3 ± 5.9 <
0.001
71.1 ± 4.5 75.9 ± 6.0 <
0.001
75.9 ± 6.0 76.3 ± 5.9 0.644
Sex
Male 19 (11.3) 22 (18.8) 42 (8.2) 0.003 18 (15.4) 22 (18.8) 20 (17.1) 0.786
Female 149 (88.7) 95 (81.2) 472 (91.8) 99 (84.6) 95 (81.2) 97 (82.9)
Body mass index
(kg/m2)
27.4 ± 3.8 26.4 ± 3.5 26.7 ± 3.4 0.021 27.1 ± 3.5 26.4 ± 3.5 26.2 ± 3.2 0.126
Type of surgery
Unilateral 92 (54.8) 80 (68.4) 266 (51.8) 0.005 68 (58.1) 80 (68.4) 74 (63.2) 0.266
Staged bilateral 76 (45.2) 37 (31.6) 248 (48.2) 49 (41.9) 37 (31.6) 43 (36.8)
Medial history
HTN 103 (61.3) 81 (69.2) 333 (64.8) 0.387 78 (66.7) 81 (69.2) 83 (70.9) 0.777
DM 32 (19.0) 26 (22.2) 111 (21.6) 0.746 26 (22.2) 26 (22.2) 30 (25.6) 0.775
History of VTE 0 (0.0) 1 (0.9) 1 (0.2) a 0 (0.0) 1 (0.9) 1 (0.9) a
History of CAD 12 (7.1) 7 (6.0) 19 (3.7) 0.151 10 (8.5) 7 (6.0) 7 (6.0) 0.669
Heart valve
disease
0 (0.0) 0 (0.0) 3 (0.6) a 0 (0.0) 0 (0.0) 2 (1.7) a
Arrhythmia 3 (1.8) 6 (5.1) 11 (2.1) a 3 (2.6) 6 (5.1) 3 (2.6) a
Malignant disease 13 (7.7) 9 (7.7) 33 (6.4) 0.785 9 (7.7) 9 (7.7) 10 (8.5) 0.962
Values are presented as mean ± standard deviation or number (%). The statistical significance was set at p < 0.05
HTN hypertension, DM diabetes mellitus, VTE venous thromboembolism, CAD coronary artery disease
aThe frequency was too low to produce meaningful results
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patients undergoing unilateral TKA. Some studies have
reported that recurrent venous thromboemboli are more
common in male than in female patients, perhaps ex-
plained by differences in height or hormonal profiles
[26, 27]. Another study found that venous thromboem-
boli are more common in female patients after TKA
[28]. In this study, the female risk was 3.69-fold that of
male patients. The majority of VTEs (both sexes) were
calf vein thromboses. Surgery and immobilization per se
are both major risk factors for VTE [3]. In patients
undergoing bilateral staged TKA, the surgical risk dou-
bles and the between-surgery immobilization is also a
risk factor. Therefore, it is thought that bilateral staged
TKA is a risk factor for VTE.
It was found that age, sex, BMI, and type of surgery
significantly differed between the groups receiving as-
pirin, rivaroxaban, and apixaban. Thus, propensity
score-matching was performed. Each group then con-
tained 117 patients who differed only in terms of age.
The incidence of VTE was lowest in the rivaroxaban
group. Patients in the aspirin group were significantly
younger than those in the other two groups. In general,
the more advanced the age, the higher the incidence of
VTE [29, 30]. The incidence of VTE was lower in the
rivaroxaban than the aspirin group although the age of
the rivaroxaban group was higher. The rivaroxaban and
apixaban groups did not differ in terms of age.
The incidence of postoperative VTE was the lowest in
the rivaroxaban group, but the majority of VTEs in all
groups were calf vein thromboses associated with low
mortality. Only one patient developed symptomatic VTE
and none progressed to a pulmonary embolism. Since
the purpose of antithrombotic agents is to prevent fatal
complications, such as pulmonary embolism, rather than
reducing the incidence of VTE, all three agents showed
enough efficacy. Moreover, considering that aspirin is in-
expensive, aspirin can be considered cost-effective.
This study has some limitations. First, this study has a
retrospective design, and confounders could not be con-
trolled. However, propensity score-matching of several
preoperative variables was used; thus, bias was limited.
Second, ultrasonography was used to screen for postop-
erative VTE, but both CT venography and ultrasonog-
raphy were used to screen for preoperative VTE.
However, both techniques are very accurate (96.8–
97.2%) [19] and it was not considered that there was any
device bias. Third, even after propensity score-matching,
the groups significantly differed in terms of age. The
Table 3 Postoperative venous thromboembolism (VTE) of study groups
Aspirin (n = 117) Rivaroxaban (n = 117) Apixaban (n = 117) p value
Venous thromboembolism, n (%) 19 (16.2) 7 (6.0) 20 (17.1) 0.02
VTE classification, n (%)
LET I (calf vein) 18 (94.7) 7 (100.0) 20 (100.0)
LET II (popliteal/femoral vein) 1 (5.3) 0 0
LET III (common femoral/iliac vein) 0 0 0
LET IV (inferior vena cava) 0 0 0
The statistical significance was set at p < 0.05
VTE venous thromboembolism, LET lower-extremity thrombosis
Table 2 Demographic characteristics of postoperative venous thromboembolism (VTE)
Postoperative VTE (−) (n = 676) Postoperative VTE (+) (n = 123) Total (n = 799) RR (95% CI) p value
Age (years) 71.2 ± 7.1 71.9 ± 5.6 0.229
Sex
Male 79 (95.2) 4 (4.8) 83 3.94 (1.42–11.0) 0.005
Female 597 (83.4) 119 (16.6) 716
Body mass index (kg/m2) 26.7 ± 3.5 27.1 ± 3.4 0.349
Type of surgery
Unilateral 385 (87.9) 53 (12.1) 438 1.75 (1.19–2.58) 0.004
Staged bilateral 291 (80.6) 70 (19.4) 361
aPrevious agents
No 534 (85.0) 94 (15.0) 628 1.16 (0.74–1.83) 0.522
Yes 142 (83.0) 29 (17.0) 171
Values are presented as mean ± standard deviation or number (%). The statistical significance was set at p < 0.05
VTE venous thromboembolism, RR relative risk, CI confidence interval
aPreviously prescribed anticoagulant agents for other diseases regardless of total knee arthroplasty (TKA)
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rivaroxaban group is older than the aspirin group, but
age is the risk factor of VTE, so the incidence of VTE is
the lowest among the three groups. However, if there
are more patients and the ages are matched by propen-
sity score, better results can be obtained.
Conclusions
In each orally administered antithrombotic agent group,
the majority of VTEs were calf vein thromboses associ-
ated with low mortaltiy. Although the incidence of post-
operative VTE was lowest in the rivaroxaban group, all
agents showed enough efficacy as antithrombotic agents.
Considering that aspirin is inexpensive, aspirin is a cost-
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